HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Urologic Neoplasms (Urological Cancer)

Subscribe to New Research on Urologic Neoplasms

Tumors or cancer of the URINARY TRACT in either the male or the female.

Also Known As:

Urological Cancer; Urinary Tract Neoplasm; Cancer of the Urinary Tract; Neoplasms, Urologic; Urinary Tract Neoplasms; Urological Neoplasms; Cancer, Urinary Tract; Cancer, Urologic; Cancer, Urological; Cancers, Urinary Tract; Cancers, Urologic; Cancers, Urological; Neoplasm, Urinary Tract; Neoplasm, Urologic; Neoplasm, Urological; Neoplasms, Urinary Tract; Neoplasms, Urological; Tract Neoplasm, Urinary; Tract Neoplasms, Urinary; Urinary Tract Cancers; Urologic Cancers; Urologic Neoplasm; Urological Cancers; Urological Neoplasm; Cancer of Urinary Tract; Urinary Tract Cancer; Urologic Cancer

Networked: 435 relevant articles (9 outcomes, 55 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Urinary Bladder Neoplasms (Bladder Cancer)
4.	Infection
5.	Urolithiasis

Experts

1.	Rouprêt, Morgan: 5 articles (11/2015 - 03/2011)
2.	Wang, Jung-Der: 5 articles (01/2014 - 01/2009)
3.	Akaza, Hideyuki: 5 articles (02/2009 - 01/2002)
4.	Chen, Pau-Chung: 4 articles (01/2014 - 01/2009)
5.	Nakatani, Tatsuya: 4 articles (04/2005 - 12/2003)
6.	Yoshimura, Rikio: 4 articles (04/2005 - 12/2003)
7.	Shariat, Shahrokh F: 3 articles (12/2015 - 06/2013)
8.	Zigeuner, Richard: 3 articles (11/2015 - 04/2011)
9.	Babjuk, Marko: 3 articles (11/2015 - 04/2011)
10.	Kaasinen, Eero: 3 articles (11/2015 - 04/2011)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Urologic Neoplasms:

1.	Doxorubicin (Adriamycin)FDA LinkGeneric 01/01/1994 - "The Japanese Urological Cancer Research Group for Adriamycin." 01/01/1992 - "The Japanese Urological Cancer Research Group for Adriamycin." 01/01/1977 - "Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature." 01/01/1994 - "The Japanese Urological Cancer Research Group for Adriamycin has conducted a series of clinical trials to investigate the efficacy and safety of prophylactic intravesical chemotherapy for superficial bladder cancer. " 01/01/1992 - "The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin."
2.	Epirubicin (Ellence)FDA LinkGeneric 06/01/1993 - "The prophylactic efficacy of even a single instillation of epirubicin within 6 hours after transurethral resection (TUR) was proved in a randomized study (30863) of the EORTC (European Organization for Research on Therapy of Cancer) Urological Group. " 05/01/2004 - "Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml." 11/01/1999 - "Data on a total of 1732 patients from 5 studies of the Japanese Urological Cancer Research Group who were eligible to receive doxorubicin and epirubicin were analyzed. " 01/01/2002 - "[Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin]."
3.	Cisplatin (Platino)FDA LinkGeneric 04/01/1989 - "From 1985 to 1986, cisplatin (CDDP) therapy was performed 61 times in 24 patients with urological cancer. " 09/01/1984 - "Conventional and high dose cis-platinum in urological cancer." 08/01/1995 - "In conclusion, chemotherapy containing cisplatin should be considered for treatment of high stage upper urinary tract cancer." 02/01/2015 - "From March 2012 to March 2014, 46 patients with bladder or upper urinary tract cancer were treated with this regimen in our institution after failure to gemcitabine and cisplatin combination chemotherapy. " 02/01/2009 - "Thus, new anticancer drugs such as taxanes and gemcitabine were added to cisplatin-based chemotherapy, and a treatment of urological cancer is progressing."
4.	Fluorouracil (Carac)FDA LinkGeneric 06/01/2006 - "5-FU is a major anti-tumor agent, and many clinical trials have been conducted to determine the efficacy of 5-FU and fluoropyrimidine derivatives for the treatment of urological cancers. " 01/01/1987 - "Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder." 01/01/1987 - "A non-randomized clinical study on systemic combination chemotherapy was conducted by the Japanese Urological Cancer Research Group for Adriamycin to compare the effectiveness of CAP (cyclophosphamide 200-500 mg/m2, adriamycin 30-50 mg/m2 and cisplatin 30-50 mg/m2) and CAF (cyclophosphamide 200-500 mg/m2, adriamycin 30-50 mg/m2 and 5-fluorouracil 250 mg/m2) in 123 patients (104 evaluable) with advanced and/or metastatic cancer of the urinary bladder. "
5.	Methotrexate (Mexate)FDA LinkGeneric 01/01/1983 - "Twenty patients with locally advanced and/or metastatic transitional cell cancer of the urinary tract were treated with cyclophosphamide 500 mg/m2, Adriamycin (doxorubicin) 40 mg/m2 and cis-platinum (CDDP) 40 mg/m2 given every three weeks for 2 cycles, alternating with methotrexate 40 mg/m2 weekly for six weeks (CAP-M). " 07/01/1991 - "Combination chemotherapy with methotrexate, etoposide, adriamycin and cisplatin (M-EAP regimen) was administered to 4 patients with advanced epithelial cancer of the urinary tract (Methotrexate 30 mg/M2 day 1, 15 and 22; Etoposide 100 mg/M2 day 1, 2, 15 and 22; Adriamycin 30 mg/M2 day 2; Cisplatin 70 mg/M2 day 2, every 4 weeks). " 01/01/1992 - "In a cooperative study of the Japanese Urological Cancer Research Group for Adriamycin, the usefulness of chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin (M-VAC therapy) in treating advanced or recurrent bladder cancer was examined. " 03/01/1989 - "Combination chemotherapy with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC regimen) was administered to 12 patients with advanced epithelial cancer of the urinary tract in a clinical trial undertaken to assess clinical efficacy of this multiagent therapy. " 01/20/1990 - "[Combination chemotherapy with methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, and bleomycin: MVP-CAB for disseminated urological cancer]."
6.	Vinblastine (Vinblastine Sulfate)FDA Link 01/01/1992 - "In a cooperative study of the Japanese Urological Cancer Research Group for Adriamycin, the usefulness of chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin (M-VAC therapy) in treating advanced or recurrent bladder cancer was examined. " 03/01/1989 - "Combination chemotherapy with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC regimen) was administered to 12 patients with advanced epithelial cancer of the urinary tract in a clinical trial undertaken to assess clinical efficacy of this multiagent therapy. "
7.	Octreotide (Sandostatin)FDA LinkGeneric 01/01/2013 - "These results revealed that 300μg/day dose of octreotide is safe and effective for managing gastrointestinal symptoms of terminally ill urological cancer patients with MBO. " 01/01/2013 - "In the present study, we administered octreotide to urological cancer patients with MBO and evaluated the improvement of subjective symptoms, oral intake, and nasogastric intubation. " 01/01/2013 - "Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer."
8.	nuclear matrix protein 22IBA 01/01/2012 - "Genito-urinary tract cancers were identified in 210/1564 (13%) patients with an Mcm5 result and in 195/1396 (14%) patients with an NMP22 result. " 06/01/2007 - "[The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22]." 05/01/1997 - "Urinary NMP22 values were determined for 144 patients with histologically diagnosed bladder cancer, 65 patients with other urological cancers, and 171 healthy volunteers by use of a UNMP22 Test kit, which is based on an enzyme-linked immunosorbent assay. " 06/01/2001 - "False-positive results were obtained with urinary NMP22 in the patients with urinary diversion using intestine, bladder invasion from other cancers, urinary tract infection, and urolithiasis. "
9.	zoledronic acid (zoledronate)FDA Link 08/01/2010 - "Zoledronic acid treatment reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer. " 06/01/2012 - "The specialists from four disease area which is multiple myeloma, urological cancer, lung cancer and breast cancer have discussed the benefits (and risks?) of the zoledronic acid with the current status of bone management in each cancer." 01/01/2012 - "This article provides a brief overview of the characteristics of bone metastasis in urological cancers, reviews the mechanisms of bone metastasis, including the RANK/RANKL/osteoprotegerin axis, the current standard of care, zoledronic acid, and describes the efficacy of the novel bone-targeted agent denosumab in bone metastasis. "
10.	OsteoprotegerinIBA 01/01/2012 - "This article provides a brief overview of the characteristics of bone metastasis in urological cancers, reviews the mechanisms of bone metastasis, including the RANK/RANKL/osteoprotegerin axis, the current standard of care, zoledronic acid, and describes the efficacy of the novel bone-targeted agent denosumab in bone metastasis. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/1998 - "Nevertheless, application of novel therapies to reverse multidrug resistance and to increase efficacy of chemotherapy for urologic cancers should be further pursued, within the setting of controlled clinical trials, to improve on current strategies." 07/01/1998 - "Ibaraki Urological Cancer Chemotherapy Study Group]." 10/01/1991 - "Ten patients with advanced urologic cancers who were scheduled to receive at least two courses of chemotherapy were enrolled in this trial. " 03/01/2011 - "[Chemotherapy for urological cancer : usefulness and feasibility of current protocols]." 10/01/2010 - "Re: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?: W. "
2.	Combination Drug Therapy (Combination Chemotherapy) 03/01/2000 - "[New combination chemotherapy in urological cancers]." 02/01/2015 - "From March 2012 to March 2014, 46 patients with bladder or upper urinary tract cancer were treated with this regimen in our institution after failure to gemcitabine and cisplatin combination chemotherapy. " 07/01/1991 - "Combination chemotherapy with methotrexate, etoposide, adriamycin and cisplatin (M-EAP regimen) was administered to 4 patients with advanced epithelial cancer of the urinary tract (Methotrexate 30 mg/M2 day 1, 15 and 22; Etoposide 100 mg/M2 day 1, 2, 15 and 22; Adriamycin 30 mg/M2 day 2; Cisplatin 70 mg/M2 day 2, every 4 weeks). " 01/01/1987 - "A non-randomized clinical study on systemic combination chemotherapy was conducted by the Japanese Urological Cancer Research Group for Adriamycin to compare the effectiveness of CAP (cyclophosphamide 200-500 mg/m2, adriamycin 30-50 mg/m2 and cisplatin 30-50 mg/m2) and CAF (cyclophosphamide 200-500 mg/m2, adriamycin 30-50 mg/m2 and 5-fluorouracil 250 mg/m2) in 123 patients (104 evaluable) with advanced and/or metastatic cancer of the urinary bladder. " 03/01/1989 - "Combination chemotherapy with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC regimen) was administered to 12 patients with advanced epithelial cancer of the urinary tract in a clinical trial undertaken to assess clinical efficacy of this multiagent therapy. "
3.	Urinary Diversion (Ileal Conduit) 08/01/2012 - "To describe surgical urinary diversion methods, nursing management, and survivorship issues in urologic cancer survivors. " 12/01/2001 - "U-NMP22 values were determined for 38 urinary diversion patients without upper urinary tract cancer. " 06/01/2001 - "False-positive results were obtained with urinary NMP22 in the patients with urinary diversion using intestine, bladder invasion from other cancers, urinary tract infection, and urolithiasis. "
4.	Chemoprevention 10/01/2000 - "Re: re: chemoprevention of urological cancer." 04/01/2000 - "Re: Chemoprevention of urological cancer." 01/01/2000 - "The results justify the potential use of soybean foods as a practical chemoprevention approach for patients with urinary tract cancer." 01/01/2000 - "The potential of soybean foods as a chemoprevention approach for human urinary tract cancer." 06/01/1999 - "Chemoprevention of urological cancer."
5.	Lymph Node Excision (Lymph Node Dissection) 08/05/2008 - "The role of lymph-node dissection in the treatment of upper urinary tract cancer: a multi-institutional study." 08/05/2008 - "The role of lymph-node dissection in the treatment of upper urinary tract cancer: a multi-institutional study." 11/01/2014 - "We report a series of five cases that occurred after pelvic lymph node dissection for urological cancer, in addition to their clinical presentation, diagnosis, and treatment. " 06/01/2013 - "A Pubmed search was conducted to identify literature published between January 1, 2008 and March 11, 2013 addressing the role of lymphadenectomy in renal and upper urinary tract cancer. " 01/01/2013 - "Findings from the prior year suggest that - in high-volume centers - lymph node dissection for urologic cancers is equivalent between open and minimally invasive techniques in lymph node yield and short-term to medium-term oncologic results."